Abstract：
OBJECTIVE: Evaluate and compare the visual and morphological results of Pro re nata (PRN) and treat-and-extend (T&E) treatment regimens at 3 years in real world clinical practice.
METHODS: Retrospective study of patients with neovascular age macular degeneration (AMD) treated with anti-VEGF with 3 years of continuous follow-up and no previous anti-VEGF treatment. Best corrected visual acuity (BCVA), central foveal thickness (CFT) and number of intravitreal injections outcomes were tested for statistical differences between the two groups at baseline and during follow-up.
RESULTS: A total of 240 eyes were included in the study, 170 in the PRN group and 70 in the T&E group. At 12 months, mean BCVA (ETDRS letters) gain from baseline was at its highest point in the T&E group (+6.38±13.32; p=0.25). In the PRN group, BCVA peaked at 3 months and slowly decreased until end of follow-up. With both regimens, from baseline, CFT continued to decrease until the second year (PRN -138.81 [-846.7 to +162.77] and T&E -81 [-604 to +100] μm, p=0.06). After that, T&E group maintained this tendency, reaching the lowest CFT value at 36 months, whereas PRN group showed an increased in CFT values (PRN -104 [-807.7 to +297] μm and T&E -103 [-575 to +244], μm p=0.63). Patients treated with T&E regimen received a significantly higher number of injections (PRN 16.3±7.6 vs T&E 23.9 ±9.4, p<0.01).
CONCLUSIONS: Our results demonstrated a trend towards for T&E to achieve higher marks in BCVA, peaking at 12 months, and lower CFT thickness at the end of three years. Despite the higher number of injections performed in the T&E group the mean BCVA reverts to baseline values at 3 years.
METHODS: Retrospective study of patients with neovascular age macular degeneration (AMD) treated with anti-VEGF with 3 years of continuous follow-up and no previous anti-VEGF treatment. Best corrected visual acuity (BCVA), central foveal thickness (CFT) and number of intravitreal injections outcomes were tested for statistical differences between the two groups at baseline and during follow-up.
RESULTS: A total of 240 eyes were included in the study, 170 in the PRN group and 70 in the T&E group. At 12 months, mean BCVA (ETDRS letters) gain from baseline was at its highest point in the T&E group (+6.38±13.32; p=0.25). In the PRN group, BCVA peaked at 3 months and slowly decreased until end of follow-up. With both regimens, from baseline, CFT continued to decrease until the second year (PRN -138.81 [-846.7 to +162.77] and T&E -81 [-604 to +100] μm, p=0.06). After that, T&E group maintained this tendency, reaching the lowest CFT value at 36 months, whereas PRN group showed an increased in CFT values (PRN -104 [-807.7 to +297] μm and T&E -103 [-575 to +244], μm p=0.63). Patients treated with T&E regimen received a significantly higher number of injections (PRN 16.3±7.6 vs T&E 23.9 ±9.4, p<0.01).
CONCLUSIONS: Our results demonstrated a trend towards for T&E to achieve higher marks in BCVA, peaking at 12 months, and lower CFT thickness at the end of three years. Despite the higher number of injections performed in the T&E group the mean BCVA reverts to baseline values at 3 years.
摘要：
目的：评估和比较在现实世界临床实践中3年前再纳塔（PRN）和治疗和扩展（T＆E）治疗方案的视觉和形态学结果。
方法：对接受抗VEGF治疗的新生血管性年龄黄斑变性（AMD）患者进行回顾性研究，连续随访3年，之前没有接受抗VEGF治疗。最佳矫正视力（BCVA），在基线和随访期间,对两组中心凹厚度(CFT)和玻璃体腔注射次数的结果进行统计学差异检验.
结果：本研究共纳入240只眼，PRN组170人，T&E组70人。12个月时,在T&E组中,从基线开始的平均BCVA(ETDRS字母)增益达到最高点(+6.38±13.32;p=0.25).在PRN组中，BCVA在3个月时达到峰值，并缓慢下降直至随访结束。有了这两种方案，从基线，CFT持续下降，直到第二年(PRN-138.81[-846.7至+162.77]和T&E-81[-604至+100]μm，p=0.06)。之后,T&E集团保持这种趋势，在36个月时达到最低CFT值，而PRN组显示CFT值增加(PRN-104[-807.7至+297]μm和T&E-103[-575至+244]，μmp=0.63)。接受T&E方案治疗的患者接受的注射次数明显更高(PRN16.3±7.6vs.T&E23.9±9.4,p<0.01)。
结论：我们的结果表明，T＆E在BCVA中获得更高分数的趋势，在12个月达到峰值，三年末，CFT厚度降低。尽管T&E组的注射次数较多，但平均BCVA在3年时恢复到基线值。
方法：对接受抗VEGF治疗的新生血管性年龄黄斑变性（AMD）患者进行回顾性研究，连续随访3年，之前没有接受抗VEGF治疗。最佳矫正视力（BCVA），在基线和随访期间,对两组中心凹厚度(CFT)和玻璃体腔注射次数的结果进行统计学差异检验.
结果：本研究共纳入240只眼，PRN组170人，T&E组70人。12个月时,在T&E组中,从基线开始的平均BCVA(ETDRS字母)增益达到最高点(+6.38±13.32;p=0.25).在PRN组中，BCVA在3个月时达到峰值，并缓慢下降直至随访结束。有了这两种方案，从基线，CFT持续下降，直到第二年(PRN-138.81[-846.7至+162.77]和T&E-81[-604至+100]μm，p=0.06)。之后,T&E集团保持这种趋势，在36个月时达到最低CFT值，而PRN组显示CFT值增加(PRN-104[-807.7至+297]μm和T&E-103[-575至+244]，μmp=0.63)。接受T&E方案治疗的患者接受的注射次数明显更高(PRN16.3±7.6vs.T&E23.9±9.4,p<0.01)。
结论：我们的结果表明，T＆E在BCVA中获得更高分数的趋势，在12个月达到峰值，三年末，CFT厚度降低。尽管T&E组的注射次数较多，但平均BCVA在3年时恢复到基线值。
